Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-05-17
2011-05-17
Horlick, Kenneth R. (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200
Reexamination Certificate
active
07943311
ABSTRACT:
A method for determining the risk of adverse effects of irinotecan (CPT-11), a synthetic anticancer drug, by detecting polymorphisms in the TATA box within the promoter region of the UDP-glucuronosyl transferase gene. A kit for detecting the adverse effects of irinotecan containing at least one pair of nucleic acid probes.
REFERENCES:
patent: 6274310 (2001-08-01), Habener et al.
patent: 7582427 (2009-09-01), Sato et al.
patent: 2004/0058363 (2004-03-01), Hasegawa et al.
patent: 2004/0203034 (2004-10-01), Ratain et al.
patent: 2006/0160074 (2006-07-01), Dorn et al.
Meinkoth et al., Analytical Biochemistry 138, 267-284 (1984).
Han et al, Journal of Clinical Oncology, 2006, 24(15), pp. 2237-2244.
Smith at al, Toxicology in Vitro, 2006, 20, pp. 163-175.
Yuichi Ando, et al., “Polymorphisms of UDP-Glucuronosyltransferase Gene and Irinotecan Toxicity: A Pharamacogenetic Analysis1”, Cancer Research, vol. 60, Dec. 15, 2000, pp. 6921-6926.
Hazama Shouichi
Nakazawa Naoko
Oka Masaaki
Okamura Hiroshi
Horlick Kenneth R.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Toyo Kohan Co. Ltd.
Yamaguchi University
LandOfFree
Kits and method for determining the risk of adverse effects... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kits and method for determining the risk of adverse effects..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kits and method for determining the risk of adverse effects... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2706960